Association of *Hsa-mir-196* and *Hsa-mir-153* Expression Levels With Gastric Cancer and *H. pylori* Infection

Atefeh Moradi Nejad[1] iD, Negar Mokhtari[2] iD, Noosha Zia Jahromi[1*] iD

1. Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
2. Department of Biological Science and Technology, Najafabad Branch, Islamic Azad University, Najafabad, Iran

ABSTRACT

Background and Aim: *Helicobacter pylori* (*H. pylori*) is a bacterium that plays a significant role in the development of gastric cancer (GC). It is estimated that *H. pylori* infection is responsible for more than 70% of all gastric cancer cases worldwide. By analyzing publicly available gene expression datasets, we aimed to evaluate differentially expressed genes (DEGs) linked to the GC and *H. pylori* infection.

Materials and Methods: In this case-control study, total RNA was extracted from blood samples of 40 GC patients with 29 *H. pylori* positive samples, and 40 healthy controls with 25 *H. pylori* positive individuals. The quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression levels of *hsa-mir-19*6 and *hsa-mir-153*.

Results: Statistical analysis revealed a significant upregulation of *hsa-mir-196* and a significant downregulation of *hsa-mir-153* in the GC patients with *H. pylori* infection compared to those without infection and healthy controls.

Conclusion: *In-silico* analysis demonstrated the association of *hsa-mir-196* and *hsa-mir-153* with GC. These miRNAs are potential biomarkers for the GC associated with *H. pylori* infection and can serve as diagnostic tools for the early detection and may have prognostic value in predicting disease progression. However, further validation in larger cohorts and functional studies are necessary to fully understand their role in the GC development and assess their potential as therapeutic targets.

Keywords: Differentially Expressed Genes (DEGs), Gastric Cancer, *Helicobacter pylori*, hsa-mir-196, hsa-mir-153

Use a device to scan and read the article online

Moradi Nejad A, Mokhtari N, Zia Jahromi N. Association of *Hsa-mir-196* and *Hsa-mir-153* Expression Levels With Gastric Cancer and *H. pylori* Infection. Iran J Med Microbiol. 2024;18(3):163-71.

Download citation: BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to: Mendeley Zotero RefWorks

1. Introduction

Gastric cancer (GC) is a significant global health burden, accounting for a substantial number of cancer-related deaths each year **(1)**. Among the various risk factors identified, *Helicobacter pylori (H. pylori)* has garnered attention due to its association with the GC development and progression **(2)**. The *H. pylori* infection is a widespread chronic bacterial infection that affects over the half of the world's population **(3)**. Although most infected individuals remain asymptomatic, some develop progressive gastritis, peptic ulcers, and eventually gastric cancer **(4)**. The exact mechanisms by which *H. pylori* contributes to the GC are not fully understood **(5)**.

However, it is widely recognized that *H. pylori* can induce a persistent inflammatory response, disrupt cellular homeostasis, and promote the genetic and epigenetic alterations within the gastric epithelium **(6)**.

MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules that play crucial roles in the post-transcriptional gene regulation **(7)**. They are approximately 22 nucleotides in length and are highly conserved across the species. MiRNAs are involved in a wide range of biological processes, including development, cell differentiation, proliferation, and

apoptosis **(8)**. They have also been implicated in various diseases including cancer, cardiovascular disorders, and neurological conditions. MiRNAs can function by binding to the 3' untranslated region (UTR) of the target messenger RNAs (mRNAs), leading to the mRNA degradation or translational repression **(9)**. This interaction between miRNAs and their target mRNAs is guided by the sequence complementarity, with partial complementarity resulting in translational repression and near-perfect complementarity leading to the mRNA degradation **(10)**.

MiRNAs play a pivotal role in gene expression regulation and modulate immune responses during infections. Numerous studies have shown that *H. pylori* infection induces changes in miRNA expression profiles within gastric epithelial cells and immune cells. Dysregulation of miRNAs during *H. pylori* infection can result in abnormal expression of the target genes associated with immune responses, inflammation, and cell proliferation **(11-13)**. For example, *H. pylori*-induced upregulation of *miR-155* has been associated with increased pro-inflammatory cytokine production **(14)**, while downregulation of *miR-146a* has been implicated in chronic inflammation and gastric carcinogenesis **(15, 16)**.

Understanding the intricate relationship between miRNAs, *H. pylori* infection, and gastric cancer holds great promise for improving the diagnosis, prognosis, and treatment strategies **(17)**. To this aim we attempted to identify the differentially expressed miRNAs associated with *H.pylori* infection via *in silico* methods and further detect its connection to gastric cancer via quantitative PCR method.

2. Materials and Methods

Sample Collection and RNA Extraction

A total of 80 blood samples were obtained from Al-Zahra Hospital in Isfahan, Iran. Among these samples, 40 were individuals with gastric cancer of which 29 samples were tested positive and 11 were tested negative for *H. pylori* infection. Forty other samples from healthy controls comprised of 25 *H. pylori* positive and 15 *H. pylori* negative samples. The samples infected with *H. pylori* were confirmed using the stool PCR test, and the cancer status of the samples was confirmed by a pathologist. In order to investigate the effect of gene expression on this cancer, two healthy and disease samples were selected with no significant difference in age and gender.

Demographic data regarding the collected samples have been demonstrated in Table 1. The collection of blood samples was conducted in accordance with the guidelines provided by the Ethics Committee of Islamic Azad University, Shahrekord branch, with approval number IR.IAU.SHK.REC.1401.083. These guidelines adhered to the principles outlined in the 64th World Medical Association General Assembly of Helsinki declaration, which was amended in October 2013. Furthermore, informed consent was obtained from all individuals included in the study.

The extraction of total RNA was carried out using Trizol reagent from the blood samples (Promega Co., based in Madison, WI, USA), then, the cDNA synthesis was performed using miScriptII® RT Kit (QIAGEN, Germany). QRT-PCR amplification was conducted by SYBR® Premix Ex Taq™ II (Takara, Dalian, China) using Qiagen Rotor-Gene real-time PCR instrument. The cycling parameters were set according to the instructions provided by the Takara kit including: initial denaturation: 95°C for 30 sec, amplification (40 cycles) of denaturation: 95°C for 5-10 sec, and annealing and extension: 60°C for 20-30 sec. Data were analyzed based on the $2^{-\Delta\Delta Ct}$ method and the statistical analysis was performed using Prism software. The U6 snRNA was used as the control housekeeping gene. The miRNAs primer sets (Catalog #BON209002, Bonbiotech, BONmiR, Iran) were used for the qRT-PCR.

In-silico DEG Analysis

DEG analysis was performed on the expression data (GSE19769) from GEO database **(18)** using limma package **(19)** in R-based software (version 4.2.1) to identify the miRNAs with significant differential expression between the *H. pylori* positive and control samples. The differentially expressed miRNAs were selected based on the predefined criteria including fold change, p-value and adjusted p-value. First, the raw miRNA expression data was preprocessed. Then, statistical analysis was conducted to identify differentially expressed miRNAs between the *H. Pylori* positive and control groups.

For this purpose, the limma package was applied. This package considers the distribution of miRNAs and applies the statistical linear model to assess the significance of differences in the expression levels. Adjustments for multiple testing, such as the Benjamini-Hochberg procedure, controls the false discovery rate (FDR). Differentially expressed miRNAs were then selected based on the combination of fold change and statistical significance. The thresholds for both parameters were fold change of ≥1 and p-value of ≤0.05, to identify the miRNAs with substantial expression differences.

To validate the results of DEG analysis, quantitative real-time PCR (qRT-PCR) was performed. This technique confirmed the differential expression

patterns of the selected miRNAs and further validated their potential functional relevance. Finally, the top10 most expressed genes of the DEG analysis are reported in Table 2. The most upregulated and downregulated miRNAs along with their fold changes and statistical significance are presented in Table 3.

Table 1. Demographic data of the samples.

Total	Cancer	Normal	P-value	95% CI
H. pylori	40	40		
H. pylori +	29	25	0.0064	57.17 to 83.89
H. pylori -	11	15		16.11 to 42.83
Age				
<50	20	18	>0.9999	35.20 to 64.80
>50	20	22		35.20 to 64.80
Sex				
Male	28	26	0.0166	54.57 to 81.93
Female	12	14		18.07 to 45.43
Stage				
I-II	10			
III	21	-	<0.0001	-
IV	9			

Table 2. Differentially expressed miRNAs.

Differentially expressed miRNAs	P-value	Adj P-value	Logfc
hsa-mir-196b-5p	0.0361599	4.75E-03	4.13
hsa-miR-302a*	0.0148171	1.28E-03	3.98
hsa-miR-523	0.0185678	1.67E-03	3.69
hsa-miR-596	0.0186046	1.73E-03	3.35
hsa-miR-571	0.0106511	8.05E-04	3.22
hsa-miR-548b	0.0201644	1.99E-03	2.95
hsa-miR-384	0.0217376	2.27E-03	2.4
hsa-miR-519a	0.0200165	1.94E-03	2.39
hsa-miR-223	0.0001424	1.02E-06	2.05
hsa-miR-146b	0.0003573	3.86E-06	1.93
hsa-mir-153-3p	0.0026733	1.37E-04	-5.81
hsa-miR-411	0.0005893	1.36E-05	-5.96
hsa-miR-204	0.0186046	1.74E-03	-3.69
hsa-miR-96	0.0309951	3.74E-03	-3.34

Differentially expressed miRNAs	P-value	Adj P-value	Logfc
hsa-miR-383	0.0461288	6.75E-03	-3.07
hsa-miR-299-5p	0.1342025	3.26E-02	-2.32
kshv-miR-K12-10a	0.0986511	2.11E-02	-2.53
kshv-miR-K12-10b	0.1235873	2.89E-02	-2.38
hsa-miR-373	0.1732536	4.74E-02	-2.13
hsa-miR-369-5p	0.2835105	9.33E-02	-1.77

Table 3. Most upregulated and most downregulated miRNAs.

Differentially expressed miRNAs	P-value	Adj P-value	Logfc	Average expression
hsa-miR-196b-5p	4.75e-03	0.0361599	4.13	*H. pylori* positive :4.648
				H. pylori negative:0.7228
hsa-miR-153-3p	1.37e-04	0.0026733	-5.81	*H. pylori* positive :0.22
				H. pylori negative:3.045

3. Results

Differential Expression Analysis

The DEG analysis identified the miRNAs that exhibited significant differential expression between the *H. pylori* positive and normal samples. Based on the statistical analysis, a subset of miRNAs showed significant differential expression. Among them, 239 miRNAs were found to be significantly upregulated, while 318 miRNAs were significantly downregulated in the *H. pylori* positive samples compared to the control samples. The differential expression of these miRNAs was determined based on the predefined criteria, including a fold change threshold of 1 and a statistical significance level of P=0.05. Figure S1 shows the volcano plot demonstrating the differentially expressed miRNAs.

Real-Time PCR Validation

The most upregulated and the most downregulated miRNAs identified using real-time PCR were *hsa-miR-196b-5p* and *hsa-miR-153-3p*, respectively that were selected for the validation based on their LogFC and statistical significance in the DEG analysis. As shown in Figure 1, the real-time PCR results confirmed the significant upregulation of *hsa-miR-196b-5p* (*P*=0.0007) and significant downregulation of *hsa-miR-153-3p* in the tumor samples compared to the control samples (*P*<0.0001).

The *hsa-miR-196b-5p* exhibited 17.5 fold higher expression levels, indicating their increased abundance in the *H. pylori* condition. On the other hand, *hsa-mir-153-3p* showed 11.62 fold lower expression levels in the *H. pylori* positive samples relative to the control samples (Figure 2).

Statistical analysis was performed on the real-time PCR data to evaluate the significant level of the differential expression. The results revealed a significant difference (*P*<0.05) in the expression levels of the validated miRNAs between the *H. pylori* positive and control samples. No significant association was found between the age, sex, and disease stage, and the relative expression of *hsa-miR-196b-5p* or *hsa-miR-153-3p*.

Also, receiver operating characteristic (ROC) analysis was conducted and the ROC curve was illustrated in Figure 3.

Figure 1. Relative expression levels of *hsa-miR-196b-5p* and *hsa-miR-153-3p* in tumor vs. normal samples. (Designed by Authors, 2024)


Figure 2. Relative expression levels of *hsa-miR-196b-5p* and *hsa-miR-153-3p* in *H. pylori* + vs. *H. pylori* – samples. (Designed by Authors, 2024)


Figure 3. ROC curves of *hsa-miR-196b-5p* and *hsa-miR-153-3p*. (Designed by Authors, 2024)

4. Discussion

The integration of differential expression analysis of GEO microarray data with real-time PCR validation has provided valuable insights into the regulatory landscape of miRNAs in *H. pylori* infection. In this study, we successfully identified the most significantly up-regulated (*hsa-miR-196b-5p*) and down-regulated (*hsa-miR-153-3p*) miRNAs using *in-silico* analysis, then, validated the expression of these miRNAs using real-time PCR. We demonstrated the association of different expressions of the *hsa-miR-196b-5p* and *hsa-miR-153-3p* with gastric cancer and *H. Pylori* infection.

The findings highlight the importance of integrating computational analyses with experimental validation to enhance our understanding of gene regulation in *H. pylori* infection, which in turn can lead to the gastric cancer (20, 21).

Some studies indicated the association between the gene expression and methylation patterns in gastric cancer (22). Particularly, this research has underlined the involvement of *H. pylori* infection in this connection. The findings of previous studies have demonstrated the complex and dynamic relationship between these factors, contributing to a better comprehension of the molecular mechanisms underlying gastric cancer (23). Mojtahedi *et al.,* reported the association of iceA and vacA allelic genes with *H. pylori* strains and gastric disorders (24). In another study, Reyes *et al.,* showed that *H. pylori* infection induces chronic inflammation that affects the gastric epithelium, which can lead to DNA damage and the promotion of precancerous lesions (25). Yao *et al.,* identified novel diagnostic or prognostic markers for the gastric cancer through miRNA profiling using high-throughput sequencing or microarray technology. By means of this approach, they were able to identify miRNAs that showed differential expression in gastric cancer compared to the normal samples (26).

Among the validated miRNAs, *hsa-miR-196b-5p* demonstrated significant upregulation, suggesting its potential role as a positive regulator in *H. pylori* infection. These findings are in line with previous studies that have implicated *hsa-miR-196b-5p* in similar biological processes or disease contexts. In this regard a study has indicated that loss of *TFF1* promotes the aberrant overexpression of *HOXA10* and *miR-196b-5p* by demethylation of the *HOXA10* promoter, which implies the cross-talk between the epigenetics and miRNA expression in human gastric cancer.

The overexpression of both *miR-196b* and *HOXA10* was associated with the advanced tumor stage, lymph node metastasis, and poor overall survival in gastric cancer patients (27). Another study using high-throughput sequencing and microarray technology demonstrated that the differential expression of the *hsa-miR-196b-5p* was associated with esophageal cancer (28).

Conversely, *hsa-miR-153-3p* exhibited a significant downregulation, indicating its potential role as a negative regulator in *H. pylori* infection. The downregulation of *hsa-miR-153-3p* suggests that it may suppress the specific target genes or pathways implicated in *H. pylori* infection. Gao *et al.,* have shown the ability of *FGD5-AS1* as a means of controlling the functions of human gastric cancer cells,

potentially by influencing the epigenetic axis of *hsa-miR-153-3p-3p/CITED2* downstream, thus linking noncoding RNA-mediated carcinogenesis to epigenetics (29). In another study, the role of two microRNAs; *miR-7* and *miR-153* was explored in the development and progression of gastric cancer induced by *H. pylori* CagA protein.

The researchers found that both *miR-7* and *miR-153* are downregulated in the gastric cancer tissues, suggesting their involvement in the disease. The experimental evidence showed that CagA protein contributes to the downregulation of these microRNAs, which in turn leads to the increased proliferation, invasion, and migration of the gastric cancer cells. The findings highlight the potential of *miR-7* and *miR-153* as the therapeutic targets and provide insights into the mechanisms underlying *H. pylori*-induced gastric carcinogenesis (30).

By integrating the computational analysis and experimental validation, our study has contributed to the growing body of knowledge regarding the non-coding RNA-mediated regulatory mechanisms underlying *H. pylori* infection (31). The identified miRNAs, *hsa-miR-196b-5p* and *hsa-miR-153-3p*, hold promise as potential biomarkers or therapeutic targets in *H. pylori* infection. The validation of these miRNAs strengthens their candidacy for further investigation and exploration in the future studies. It is noteworthy that the mentioned miRNAs are differentially expressed in *H. pylori* condition, therefore it is deductible from this study results that the mentioned biomarkers may play a crucial role in gastric carcinogenesis.

It is important to note that the present study has certain limitations. Firstly, our analysis was limited to the available GEO microarray data, and additional experiments utilizing other datasets or platforms could further validate and expand our findings. Secondly, while real-time PCR is a robust and widely used technique for the gene expression analysis, it is essential to acknowledge that it has its own limitations, including the potential for the primer bias and variability in the amplification efficiency. Future studies could consider employing alternative validation methods such as RNA sequencing (RNA-seq) or functional assays to complement and verify our findings.

5. Conclusion

In conclusion, the integration of DEG analysis of GEO microarray data with real-time PCR validation has unveiled crucial miRNAs and provided valuable insights into their potential roles in *H. pylori* infection. The findings contribute to the growing body of knowledge in the field of *H. pylori* infection and pave the way for

the future research endeavors aimed at therapeutic interventions and personalized medicine. Further investigations and functional studies are required to fully comprehend the regulatory mechanisms and clinical implications of these miRNAs in *H. pylori* infection. The comprehensive understanding of the miRNA-mediated regulation in *H. pylori* infection will ultimately contribute to the development of novel therapeutic strategies and improve the patients' outcomes.

Acknowledgment

The authors would like to express their gratitude to all colleagues who have contributed to the completion of this research project.

Ethical Considerations

The collection of blood samples was conducted in accordance with the guidelines provided by the Ethics Committee of Islamic Azad University, Shahrekord branch, with approval number IR.IAU.SHK.REC.1401.083. These guidelines adhered to the principles outlined in the 64th World Medical Association General Assembly of Helsinki declaration, which was amended in October 2013. Furthermore, informed consent was obtained from all individuals included in the study.

Authors' Contributions

The authors wish to declare their equal contribution for this research paper. All authors, have significantly contributed to the conception, design, and execution of the study. Throughout the research process, they jointly collected, analyzed, and interpreted the data. Their collaborative effort was essential in drafting and revising the manuscript, ensuring a cohesive and comprehensive presentation of the findings.

Funding

This research was conducted without external funding. The authors acknowledge that no specific grant or financial support from any organization was received for the completion of this study. The independence afforded by the absence of external funding underscores the authors' commitment to impartiality and objectivity in the research process.

Conflict of Interest

The authors declare no conflicts of interest related to the research, authorship, and publication of this paper. No financial or personal relationships with organizations or individuals that could influence the research findings or the interpretation of the results are present. This work has been conducted with the utmost integrity, and any potential biases have been rigorously addressed.

References

1. Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534-42. [DOI:10.1016/j.cgh.2019.07.045][PMID][PMCID]

2. Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter pylori associated global gastric cancer burden. Front Biosci-Landmark. 2009; 14(4):1490-504. [DOI:10.2741/3320] [PMID] [PMCID]

3. Go M. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16:3-15. [PMID] [DOI:10.1046/j.1365-2036.2002.0160s1003.x]

4. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F. H. pylori infection and gastric cancer: state of the art. Int J Oncol. 2013; 42(1):5-18. [DOI:10.3892/ijo.2012.1701] [PMID]

5. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep. 2011;16(1):1-7. [DOI:10.1179/174329211X12968219310756] [PMID] [PMCID]

6. Ishiguro H, Kimura M, Takeyama H. Role of microRNAs in gastric cancer. World J Gastroenterol. 2014;20(19):5694-9. [DOI:10.3748/wjg.v20.i19.5694] [PMID] [PMCID]

7. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol. 2010;220(2):126-39. [DOI:10.1002/path.2638] [PMID]

8. Tüfekci KU, Meuwissen RLJ, Genç Ş. The role of microRNAs in biological processes. In miRNomics: microRNA biology and computational analysis. 2014. 1st ed. pp.15-31. Totowa, NJ, U.S.A.: Humana Press. [DOI:10.1007/978-1-62703-748-8_2] [PMID]

9. Shyu AB, Wilkinson MF, Van Hoof A. Messenger RNA regulation: to translate or to degrade. EMBO J. 2008;27(3):471-81. [PMID] [PMCID] [DOI:10.1038/sj.emboj.7601977]

10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-33. [DOI:10.1016/j.cell.2009.01.002][PMID][PMCID]

11. Gracias DT, Katsikis PD. MicroRNAs: key components of immune regulation. In Crossroads between innate and adaptive immunity III. 2011. 1st ed. pp.:15-26. New York, NY, U.S.A.: Springer. [PMID] [DOI:10.1007/978-1-4419-5632-3_2]

12. Cadamuro ACT, Rossi AFT, Maniezzo NM, Silva AE. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. World J Gastroenterol. 2014;20(6): 1424-37. [DOI:10.3748/wjg.v20.i6.1424] [PMID] [PMCID]

13. Libânio D, Dinis-Ribeiro M, Pimentel-Nunes P. Helicobacter pylori and microRNAs: Relation with innate immunity and progression of preneoplastic conditions. World J Clin Oncol. 2015;6(5):111-32. [DOI:10.5306/wjco.v6.i5.111] [PMID] [PMCID]

14. Hocès De La Guardia A, Staedel C, Kaafarany I, Clément A, Roubaud Baudron C, Mégraud F, et al. Inflammatory cytokine and microRNA responses of primary human dendritic cells cultured with Helicobacter pylori strains. Front Microbiol. 2013;4:236. [PMID] [PMCID] [DOI:10.3389/fmicb.2013.00236]

15. Zingone F, Pilotto V, Cardin R, Maddalo G, Orlando C, Fassan M, et al. Autoimmune atrophic gastritis: the role of miRNA in relation to Helicobacter pylori infection. Front Immunol. 2022;13:930989. [PMID] [PMCID] [DOI:10.3389/fimmu.2022.930989]

16. Shomali N, Mansoori B, Mohammadi A, Shirafkan N, Ghasabi M, Baradaran B. MiR-146a functions as a small silent player in gastric cancer. Biomed Pharmacother. 2017;96:238-45. [DOI:10.1016/j.biopha.2017.09.138] [PMID]

17. Yousefi L, Osquee HO, Ghotaslou R, Rezaee MA, Pirzadeh T, Sadeghi J, et al. Dysregulation of lncRNA in Helicobacter pylori-Infected Gastric Cancer Cells. Biomed Res Int. 2021;2021: 6911734. [DOI:10.1155/2021/6911734] [PMID] [PMCID]

18. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-10. [DOI:10.1093/nar/30.1.207] [PMID] [PMCID]

19. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47-e. [DOI:10.1093/nar/gkv007] [PMID] [PMCID]

20. Lim JY, Yoon SO, Seol S-Y, Hong SW, Kim JW, Choi SH, et al. Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World J Gastroenterol. 2013; 19(41):7078-88. [DOI:10.3748/wjg.v19.i41.7078] [PMID] [PMCID]

21. Badr MT, Omar M, Häcker G. Comprehensive Integration of Genome-Wide Association and Gene Expression Studies Reveals Novel Gene Signatures and Potential Therapeutic Targets for Helicobacter pylori-Induced Gastric Disease. Front Immunol. 2021;12:624117. [PMCID] [DOI:10.3389/fimmu.2021.624117] [PMID]

22. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clinica Chimica Acta. 2013;424:53-65. [DOI:10.1016/j.cca.2013.05.002] [PMID]

23. Liu D, Ma X, Yang F, Xiao D, Jia Y, Wang Y. Discovery and validation of methylated-differentially expressed genes in Helicobacter pylori-induced gastric cancer. Cancer Gene Ther. 2020;27(6):473-85. [PMID] [DOI:10.1038/s41417-019-0125-7]

24. Mojtahedi A, Fakhrieh Asl S, Aminian K, Pourvahedi M, Saadat F, Fallah Karkan M. The association between iceA and vacA allelic gene variations of Helicobacter pylori strains and gastric disorders. Gene Rep. 2018;13:94-8. [DOI:10.1016/j.genrep.2018.09.006]

25. Reyes VE. Helicobacter pylori and Its Role in Gastric Cancer. Microorganisms. 2023;11(5): 1312. [DOI:10.3390/microorganisms11051312] [PMID] [PMCID]

26. Yao Y, Suo A-L, Li Z-F, Liu L-Y, Tian T, Ni L, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2(6):963-70.

27. Shao L, Chen Z, Peng D, Soutto M, Zhu S, Bates A, et al. Methylation of the HOXA10 Promoter Directs miR-196b-5p-Dependent Cell Proliferation and Invasion of Gastric Cancer Cells. Mol Cancer Res. 2018;16(4):696-706. [PMCID] [DOI:10.1158/1541-7786.MCR-17-0655] [PMID]

28. Liu S-G, Qin X-G, Zhao B-S, Qi B, Yao WJ, Wang T-Y, et al. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 2013;5(5): 1639-42. [DOI:10.3892/ol.2013.1251] [PMID] [PMCID]

29. Gao Y, Xie M, Guo Y, Yang Q, Hu S, Li Z. Long non-coding RNA FGD5-AS1 regulates cancer cell proliferation and chemoresistance in gastric cancer through miR-153-3p/CITED2 axis. Front genet. 2020;11:715. [PMID] [PMCID] [DOI:10.3389/fgene.2020.00715]

30. Song Y, Guo D, Liu J-F, Ge L-N, Liu P, Qu Y-M, et al. Downregulation of miR 7 and miR 153 is involved in Helicobacter pylori CagA induced gastric carcinogenesis and progression. Int J Oncol. 2023;63(1):1-14. [DOI:10.3892/ijo.2023.5527] [PMID] [PMCID]

31. Wang C, Hu Y, Yang H, Wang S, Zhou B, Bao Y, et al. Function of Non-coding RNA in Helicobacter pylori-Infected Gastric Cancer. Front Mol Biosci. 2021;8:649105. [PMCID] [DOI:10.3389/fmolb.2021.649105] [PMID]